A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Molly E. Fouts, Diane Medina, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences